Samsung Biologics Co Ltd
KRX:207940
Samsung Biologics Co Ltd
KRX:207940
Price:
784 000 KRW
0.38%
Market Closed
Updated:
May 16, 2024
P/OCF
Price to OCF
Price to OCF
33.5
Current
75.7
Median
23.7
Industry
Lower
than median
Higher
than industry value
Price to Operating Cash Flow (P/OCF) ratio is a valuation multiple that measures the value of a company’s market capitalization relative to the operating cash flow it generates. Some analysts prefer P/OCF over P/E since earnings can be more easily manipulated than cash flows.
P/OCF
=33.5
Market Cap
/
55.8T
Operating Cash Flow
1.7T
All Countries
| Market Cap | P/OCF | ||||
|---|---|---|---|---|---|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
55.8T KRW | 33.5 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
231.7B USD | 27.5 | |
| US |
|
Danaher Corp
NYSE:DHR
|
195B USD | 28.1 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
45.2B USD | 23.1 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
42.5B USD | 19.9 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
38B CHF | 27.4 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
32.5B USD | 32.6 | |
| IE |
|
ICON PLC
NASDAQ:ICLR
|
26.3B USD | 20 | |
| US |
|
West Pharmaceutical Services Inc
NYSE:WST
|
25.5B USD | 33.9 | |
| US |
|
Waters Corp
NYSE:WAT
|
21.5B USD | 32.2 | |
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
19B EUR | 29.8 |
P/OCF Forward Multiples
Forward P/OCF multiple is a version of the P/OCF ratio that uses forecasted operating cash flow for the P/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/OCF
N/A
2-Years Forward
P/OCF
N/A
3-Years Forward
P/OCF
N/A
You don't have any saved screeners yet
